



# 18<sup>TH</sup> INTERNATIONAL SYMPOSIUM ON THROMBOEMBOLISM

14-15 OCTOBER 2011, THE QUEEN ELIZABETH II CONFERENCE CENTRE, LONDON, UK

## COURSE HIGHLIGHTS

Venous Thrombosis  
Arterial Thrombosis  
Cancer-Associated Thrombosis

Meet the Expert Sessions  
Case Presentations  
Workshops  
Debate

## Faculty

**Juan Arcelus**  
University of Granada,  
Granada, Spain

**Jean-Pierre Bassand**  
University Hospital,  
Besançon, France

**Christoph Bode**  
University Hospital Freiburg,  
Freiburg, Germany

**Henri Bounameaux**  
University Hospital of Geneva,  
Geneva, Switzerland

**Harry Büller**  
Academic Medical Center,  
Amsterdam, The Netherlands

**Stuart Connolly**  
McMaster University,  
Hamilton, Ontario, Canada

**John Eikelboom**  
McMaster University,  
Hamilton, Ontario, Canada

**Keith AA Fox**  
University of Edinburgh,  
Edinburgh, UK

**Ian Greer**  
University of Liverpool,  
Liverpool, UK

**Christopher Granger**  
Duke University Medical Center,  
Durham, North Carolina, USA

**Sylvia Haas**  
Technical University,  
Munich, Germany

**Lord Kakkar**  
University College London,  
London, UK

**Vijay Kakkar**  
Thrombosis Research Institute,  
London, UK

**Craig Kessler**  
Georgetown University Medical  
Center, Washington, DC, USA

**Alok Khorana**  
University of Rochester,  
Rochester, New York, USA

**Mark Levine**  
McMaster University,  
Hamilton, Ontario, Canada

**Gilles Montelecot**  
Hôpital Pitie-Salpêtrière,  
Paris, France

**Paolo Prandoni**  
University of Padua, Padua, Italy

**Alexander GG Turpie**  
McMaster University,  
Hamilton, Ontario, Canada

**Freek Verheugt**  
University Hospital,  
Nijmegen, The Netherlands

**FINAL ANNOUNCEMENT**



[www.tri-ist.com](http://www.tri-ist.com)



# 18<sup>TH</sup> INTERNATIONAL SYMPOSIUM ON THROMBOEMBOLISM

Dear Colleagues,

The organising committee is pleased to invite you to the 18th International Symposium on Thromboembolism (IST) in London, United Kingdom from 14 - 15 October 2011. The annual IST presents clinicians with a unique opportunity to update themselves on the latest developments in thromboembolism.

As you will see from the agenda, this meeting combines an exciting blend of plenary sessions and a debate on topics of common interest, as well as 'meet the expert' sessions and workshops. The workshops are focused on specialities and are designed to enhance interactivity, offering the unique chance to explore varied topics ranging from thromboembolic stroke, to special populations. All sessions aim to help us improve patient care.

As in previous years, we are delighted to welcome colleagues from across the world to this important meeting, which we hope will be another excellent opportunity to participate in this valuable educational programme.

I look forward to welcoming you to London this autumn.

With best wishes,

Lord Kakkar  
Chairman





# 18<sup>TH</sup> INTERNATIONAL SYMPOSIUM ON THROMBOEMBOLISM

## Agenda

### DAY 1 – Friday 14 October 2011

- 08.45-09.00**      **Welcome**      *Mountbatten Room*  
*Lord Kakkar, UK (Chairman)*
- 09.00-10.30**      **Plenary Session I: Cancer-Associated Thrombosis**      *Mountbatten Room*  
*Co-Chairmen: C Kessler, USA and H Büller, The Netherlands*
1. What is the appropriate duration of secondary prophylaxis?  
*Lord Kakkar, UK*
  2. Is there a role for primary VTE prophylaxis in the medical oncology patient?  
*C Kessler, USA*
  3. Do we really understand the burden of thrombosis in cancer?  
*M Levine, Canada*
- 10.30-11.00**      **Coffee Break**      *Mountbatten Lounge*
- 11.00-12.30**      **Plenary Session II: Venous Thrombosis**      *Mountbatten Room*  
*Co-Chairmen: S Haas, Germany and VV Kakkar, UK*
1. What is the role of parenteral therapy in VTE treatment?  
*H Büller, The Netherlands*
  2. Is there a balance of risk and benefit for prophylaxis in acutely ill medical patients?  
*J Eikelboom, Canada*
  3. Surgical patients and extended thromboprophylaxis: Is there a real need?  
*J Arcelus, Spain*
- 12.30-13.00**      **Novel Oral Anticoagulant Update: Rivaroxaban**      *AGG Turpie, Canada*
- 13.00-14.30**      **Lunch**      *Mountbatten Lounge*
- 14.30-15.30/  
16.00-17.00**      **Workshops (Two 15 minute talks followed by 30 minute discussion  
(Delegates to attend 2 workshops and use coffee break to change rooms.))**
- 1. Special Populations**
    - a) Women's health *I Greer, UK*
    - b) Recurrent thromboembolism *P Prandoni, Italy*
  - 2. Cancer-Associated Thrombosis**
    - a) Can we predict thrombosis risk in the cancer patient? *C Kessler, USA*
    - b) Should we treat incidental thrombi? *M Levine, Canada*
  - 3. Acute Coronary Syndrome**
    - a) Drugs and devices to optimize reperfusion of ST-elevation myocardial infarction  
*G Montalescot, France*
    - b) Adjunctive therapy after ACS: Too much or too little? *KAA Fox, UK*
  - 4. Thromboembolic Stroke**
    - a) A continuing role for warfarin? *AGG Turpie, Canada*
    - b) Can we improve patient outcomes through treating co-morbidities?  
*JP Bassand, France*
- 15.30-16.00**      **Coffee Break**      *Mountbatten Lounge*



# 18<sup>TH</sup> INTERNATIONAL SYMPOSIUM ON THROMBOEMBOLISM

## DAY 2 – Saturday 15 October 2011

<b>09.00-10.00</b>	<b>Meet the Expert Sessions</b>	<i>Break-Out Rooms</i>
	<b>Novel antithrombotic agents – A personal view</b> Session A: <i>AGG Turpie, Canada</i> Session B: <i>H Büller, The Netherlands</i> Session C: <i>H Bounameaux, Switzerland</i> Session D: <i>J Arcelus, Spain</i>	
<b>10.00-10.30</b>	<b>Coffee Break</b>	<i>Mountbatten Lounge</i>
<b>10.30-12.00</b>	<b>Plenary Session III: Arterial Thrombosis</b> <i>Co-Chairmen: JP Bassand, France and AGG Turpie, Canada</i>	
	<ol style="list-style-type: none"><li>1. Better recognition of sub-clinical AF could substantially reduce population burden of ischemic stroke <i>S Connolly, Canada</i></li><li>2. Do anticoagulants have a role in secondary prevention of ACS? <i>F Verheugt, The Netherlands</i></li><li>3. Will novel antiplatelet agents make aspirin use unnecessary? <i>C Bode, Germany</i></li></ol>	
<b>12.00-12.45</b>	<b>Debate</b> <i>Chairman: Lord Kakkar, UK</i> Xa inhibition is a superior target to IIa for anticoagulant therapy <b>For:</b> <i>C Granger, USA</i> <b>Against:</b> <i>S Connolly, Canada</i>	
<b>12.45-13.15</b>	<b>Novel Oral Anticoagulant Update: Apixaban</b> <i>C Granger, USA</i>	
<b>13.15-13.30</b>	<b>Closing Remarks</b>	
<b>13.30</b>	<b>Lunch</b>	

### COURSE INFORMATION

#### Description

The 18th International Symposium on Thromboembolism (IST), will focus on the advances and changes in the field of thromboembolism, while maintaining its commitment to the presentation of evidence-based medicine and helping clinicians translate research into clinical practice. The combination of the various formats at the IST allows attendees to be exposed to new data and allows for interactivity with colleagues from around the world.

#### Learning Objectives

- Evaluate current understanding of clinical evidence and key guidelines supporting cancer-associated thrombosis, venous and arterial thromboembolic disease
- Provide comprehensive overview of the state of the art in the treatment of venous and arterial thromboembolic disease
- Compare results of clinical trials to guide considerations for patient care and outcomes
- Integrate advances demonstrated in clinical trials and guidelines into daily practice

#### Target Audience

Cardiologists, oncologists, surgeons, haematologists, general practitioners, internal medicine specialists, pharmacists, nurses, and other healthcare professionals involved in the care of patients at risk or with thromboembolic disease.

Organised under the auspices of the Thrombosis Research Institute, London, United Kingdom and supported by an unrestricted educational grant from Bristol-Myers Squibb, Pfizer and Bayer Healthcare Pharmaceuticals.

